[Paroxysmal kinesigenic dyskinesia: a channelopathy? Study of 19 cases].
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000588:Amines / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D053447:Channelopathies / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D002648:Child; D002675:Child, Preschool; D002819:Chorea / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D002874:Chromosome Mapping; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005260:Female; D000077206:Gabapentin; D006801:Humans; D007223:Infant; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D012640:Seizures / Q000235:genetics / Q000523:psychology; D012744:Sex Ratio; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin
Les dyskinésies paroxystiques kinésigéniques : une << canalopathie >> ? Etude de 19 cas.